BofA raises Kymera Therapeutics price target on trial progress By Investing.com - Investing.com UK

Source: Investing.com UK · 2026-09-14T10:32:00+00:00

BofA raises Kymera Therapeutics price target on trial progress By Investing.com Investing.com UK

BestAIBroker analysis

Finance-aware sentiment: positive (+0.60 on a -1 to +1 scale).
Event classification: OTHER.
Market importance score: 31/100, weighting entity relevance, source credibility, multi-outlet coverage and recency.
Symbols referenced: KYMR, UK.